Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2025 15:33 ET | Source: Prime Biome

Prime Biome Debuts Skin-Gut Cell Turnover Breakthrough with Essential Probiotics

Tampa, April 05, 2025 (GLOBE NEWSWIRE) -- In today’s fast-paced world, maintaining optimal health can often feel overwhelming. However, the rise of probiotics has revolutionized our approach to...
May 28, 2020 14:11 ET | Source: MatriSys Bioscience

MatriSys Bioscience Inc. is pleased to announce that we have been selected as a CONNECT 2020 Cool Company

SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by...
May 26, 2020 12:25 ET | Source: MatriSys Bioscience

MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors

SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed...
May 19, 2020 03:09 ET | Source: MatriSys Bioscience

MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors

SAN DIEGO, May 19, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
March 20, 2019 19:55 ET | Source: MatriSys Bioscience

MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis

SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...
March 11, 2019 03:11 ET | Source: MatriSys Bioscience

MatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of Directors

SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin...
January 03, 2019 03:01 ET | Source: MatriSys Bioscience

MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing

SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has...
November 12, 2018 04:11 ET | Source: MatriSys Bioscience

MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors

SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
August 21, 2017 06:00 ET | Source: MatriSys Bioscience

MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis

SAN DIEGO, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced that the first patient...
February 22, 2017 17:39 ET | Source: MatriSys Bioscience

MatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitis

SAN DIEGO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience (MatriSys Bio) is pleased to announce the publication of breakthrough scientific results from the laboratory of Dr. Richard Gallo at...